Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
3.330
-0.230 (-6.46%)
At close: Apr 6, 2026, 4:00 PM EDT
3.710
+0.380 (11.41%)
Pre-market: Apr 7, 2026, 7:32 AM EDT
Plus Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Plus Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $7.67, which forecasts a 130.33% increase in the stock price over the next year. The lowest target is $1.00 and the highest is $19.
Price Target: $7.67 (+130.33%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 23, 2026.
Analyst Ratings
The average analyst rating for Plus Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 31, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $3 | Strong Buy | Maintains | $3 | -9.91% | Mar 19, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $2 → $1 | Strong Buy | Maintains | $2 → $1 | -69.97% | Jan 23, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +20.12% | Jan 22, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +50.15% | Jan 8, 2026 |
Financial Forecast
Revenue This Year
6.36M
from 5.21M
Increased by 21.93%
Revenue Next Year
24.11M
from 6.36M
Increased by 279.39%
EPS This Year
-0.17
from -0.29
EPS Next Year
-0.09
from -0.17
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 11.9M | 29.4M | |||
| Avg | 6.4M | 24.1M | |||
| Low | 3.9M | 15.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 127.6% | 362.6% | |||
| Avg | 21.9% | 279.4% | |||
| Low | -24.8% | 147.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.14 | -0.08 | |||
| Avg | -0.17 | -0.09 | |||
| Low | -0.20 | -0.10 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.